

Claims

1. An α crystal of free form anhydride of [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid.
2. The α crystal according to claim 1, wherein the crystal exhibits peaks at diffraction angles of 9.1°, 19.4°, 22.5°, 23.3°, 23.9°, 25.7° and 26.2° in X-ray powder diffraction patterns.
3. The α crystal according to claim 2, wherein the crystal exhibits diffraction peaks at the same diffraction angles as those of the X-ray powder diffraction pattern shown in Fig. 1.
4. The α crystal according to claim 3, wherein the crystal exhibits an exothermic peak accompanying decomposition in the vicinity of 341°C according to thermal analysis (TG-DSC).
5. An AMPA receptor antagonist comprising the α crystal of free form anhydride of the compound A according to any one of claims 1 to 3, as an active ingredient.
6. A pharmaceutical comprising the crystal according to claim 3, as a therapeutic agent for treating cerebral

infarction.

7. Use of the α crystal for manufacturing a pharmaceutical for treating cerebral infarction, comprising a therapeutically effective amount of the α crystal according to any one of claims 1 to 3.

8. A method of treating cerebral infarction, comprising administering to a patient a therapeutically effective amount of the α crystal according to any one of claims 1 to 3.